Edition:
India

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

358.71USD
20 Jul 2018
Change (% chg)

$0.60 (+0.17%)
Prev Close
$358.11
Open
$358.35
Day's High
$360.50
Day's Low
$356.61
Volume
721,208
Avg. Vol
676,017
52-wk High
$370.53
52-wk Low
$249.24

Chart for

About

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis... (more)

Overall

Beta: 0.72
Market Cap(Mil.): $69,239.67
Shares Outstanding(Mil.): 211.43
Dividend: --
Yield (%): --

Financials

  BIIB.OQ Industry Sector
P/E (TTM): 21.50 30.93 32.76
EPS (TTM): 15.23 -- --
ROI: 17.59 15.07 14.61
ROE: 28.64 16.60 16.34

U.S. jobs growth lifts Wall Street, offsetting tariffs

NEW YORK U.S. stocks climbed on Friday, with the S&P 500 and the Nasdaq hitting their highest levels in two weeks, as strong U.S. jobs growth blunted the impact of an escalating U.S.-China trade dispute. | Video

07 Jul 2018

U.S. jobs growth lifts Wall Street, offsetting tariffs

NEW YORK U.S. stocks climbed on Friday, with the S&P 500 and the Nasdaq hitting their highest levels in two weeks, as strong U.S. jobs growth blunted the impact of an escalating U.S.-China trade dispute. | Video

07 Jul 2018

Biogen, Eisai's Alzheimer's drug succeeds in mid-stage trial, shares soar

Japanese drugmaker Eisai Co and Biogen Inc said that the final analysis of a mid-stage trial of their Alzheimer's drug showed positive results for patients who received the highest dose. | Video

07 Jul 2018

Biogen exercises call option to boost stake in Samsung Bioepis

SEOUL Biogen said it had exercised its option to purchase additional shares of biopharma developer Samsung Bioepis Co Ltd, a joint venture established in 2012 by Samsung BioLogics Co Ltd and Biogen.

29 Jun 2018

CORRECTED-Biogen exercises call option to boost stake in Samsung Bioepis

* Matter has bearing in regulatory scrutiny into BioLogics-sources

29 Jun 2018

Samsung BioLogics said JV partner Biogen to exercise option by late June

SEOUL, May 18 Samsung BioLogics said on Friday that its joint venture partner Biogen would exercise its call option to increase its stake to 50 pct minus one share in Samsung Bioepis.

18 May 2018

Accounting concerns wipe $6 billion off Samsung BioLogics market value

SEOUL South Korean biotech drug manufacturer Samsung BioLogics Co Ltd lost almost $6 billion in market value on Wednesday in its biggest intra-day share drop, after the country's financial watchdog said it breached accounting rules.

02 May 2018

Accounting concerns wipe $6 billion off Samsung BioLogics market value

SEOUL South Korean biotech drug manufacturer Samsung BioLogics Co Ltd lost almost $6 billion in market value on Wednesday in its biggest intra-day share drop, after the country's financial watchdog said it breached accounting rules.

02 May 2018

UPDATE 3-Accounting concerns wipe $6 bln off Samsung BioLogics market value

* Financial watchdog gives preliminary notice to co on measures

02 May 2018

BRIEF-Biogen And Neurimmune Announce Option Exercise For Alzheimer's Disease Investigational Treatment Aducanumab

* BIOGEN AND NEURIMMUNE ANNOUNCE OPTION EXERCISE FOR ALZHEIMER'S DISEASE INVESTIGATIONAL TREATMENT ADUCANUMAB

01 May 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $125.85 -0.09
Pfizer Inc. (PFE.N) $37.33 -0.03
Novartis AG (NOVN.S) CHF82.20 +1.24
Merck & Co., Inc. (MRK.N) $62.52 +0.01
Roche Holding Ltd. (ROG.S) CHF234.00 +2.05
Roche Holding Ltd. (RO.S) CHF238.60 +2.80
Bayer AG (BAYGn.DE) €92.05 -0.30
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €72.36 +0.25
GlaxoSmithKline plc (GSK.L) 1,549.80 -8.20

Earnings vs. Estimates